$1.55
-0.01 (-0.64%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ALDX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
35 interventional · 28 with posted results
Held by 14 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, D. E. Shaw & Co., Inc., MARSHALL WACE, LLP, JANE STREET GROUP, LLC, Qube Research & Technologies Ltd, +9 more) · FINRA short interest 3.1 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Clinical Trial Evaluating Patients With Primary Vitreoretinal LymphomaNCT07402876Proportion of clearance of lymphomatous vitreous cells compared across ICM and monthly ADX-2191 treatment groups after eight weeks of treatmentRandomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: ICM ADX-2191 injection, Monthly ADX-2191 injection | Primary Vitreoretinal Lymphoma | 20 | Dec 2026 | ≤ 134 d | 2026-02-11 |
| A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)NCT06685692Treatment-Emergent Adverse Event QueryNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: ADX-629, ADX-629 | Alcohol Hepatitis | 4 | 2025-06-18actual | — | 2026-06-03 |
| A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseNCT06493604Ocular discomfort symptom score over 100 minutes in the dry eye chamber at Visit 1 and Visit 3Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution | Dry Eye Disease | 116 | 2025-02-27actual | — | 2025-12-22 |
| A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseNCT06424444Subject-reported ocular discomfort score over Week 1 to Week 6Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Reproxalap ophthalmic solution (0.25%), Vehicle ophthalmic solution | Dry Eye Disease | 421 | 2024-11-03actual | — | 2025-10-01 |
| A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye DiseaseNCT06389214Ocular discomfort symptom score over 100 minutes in the dry eye chamber at Visit 2 and Visit 4Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution | Dry Eye Disease | 132 | 2024-06-11actual | — | 2025-06-05 |
| A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)NCT05717920Adverse Event (AE) QueryOpen-label · Treatment | Phase 2 | Completed | Drug: ADX-629 (Open-label) | Atopic Dermatitis | 8 | 2023-11-21actual | — | 2024-11-04 |
| A Study in Subjects With Retinitis PigmentosaNCT05392179results2026-04-23Number of Subjects With Serious Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ADX-2191, ADX-2191 | Retinitis Pigmentosa | 8 | 2023-06-23actual | — | 2026-04-23 |
| Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic SyndromeNCT05599815Adverse Event (AE) QueryOpen-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Lack of enrollment. | Drug: ADX-629 | Nephrotic Syndrome | 0 | May 2023 | — | 2024-04-17 |
| The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic ConjunctivitisNCT05234554results2026-05-14Subject-Reported Ocular Itching Score Assessed in the Allergy ChamberRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution | Allergic Conjunctivitis | 131 | 2023-04-22actual | — | 2026-05-14 |
| A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic CoughNCT05392192results2025-02-28Number of Subjects With Serious Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ADX-629, Placebo | Chronic Cough | 51 | 2023-04-13actual | — | 2025-02-28 |
| A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye DiseaseNCT04735393results2025-11-26Treatment-Emergent Serious Adverse Events (TE-SAEs) of Visual Acuity DecreaseRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Reproxalap Ophthalmic Solution (0.25%), Placebo Comparator, Reproxalap Ophthalmic Solution (0.25%), Placebo Comparator | Dry Eye Disease | 757 | 2022-10-11actual | — | 2025-11-26 |
| The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative VitreoretinopathyNCT04136366results2025-07-09Recurrent Retinal Detachment Compared to Historical RatesRandomized · Open-label · PreventionStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: ADX-2191 (intravitreal methotrexate 0.8%) · Other: Standard surgical care procedure | Proliferative Vitreoretinopathy | 106 | 2022-06-14actual | — | 2025-07-09 |
| A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol LevelsNCT05487404results2025-02-28Number of Subjects With Serious Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: ADX-629, Placebo | Ethanol Intoxication | 26 | 2022-05-29actual | — | 2025-02-28 |
| A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye DiseaseNCT05424549results2025-01-15Conjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye ChamberRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution | Dry Eye Syndromes | 63 | 2022-05-09actual | — | 2025-01-15 |
| The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye DiseaseNCT05062330results2025-03-18Schirmer Test Mean Change From BaselineRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution | Dry Eye | 361 | 2022-03-04actual | — | 2025-03-18 |
| A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque PsoriasisNCT04908514results2025-03-11Change From Baseline in the Psoriasis Area and Severity Index (PASI)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ADX-629 | Plaque Psoriasis | 10 | 2022-01-21actual | — | 2025-03-11 |
| A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)NCT04728711results2025-02-17Number of Subjects With Serious Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ADX-629, Placebo | Atopic Asthma | 8 | 2022-01-18actual | — | 2025-02-17 |
| An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease ChamberNCT05102409results2025-02-28Change From Baseline in Ocular DiscomfortNon-randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Reproxalap Ophthalmic Solution (0.25%), Xiidra® (5% lifitegrast ophthalmic solution) | Dry Eye | 56 | 2021-10-25actual | — | 2025-02-28 |
| A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.NCT04847544results2025-02-17Number of Subjects With Serious Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ADX-629, Placebo | Covid19 | 11 | 2021-10-15actual | — | 2025-02-17 |
| The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye DiseaseNCT04674358results2025-03-19Conjunctival Redness Assessed Over 90 Minutes in the Dry Eye ChamberRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic Solution | Dry Eye, Dry Eye Syndromes | 329 | 2021-09-12actual | — | 2025-03-19 |
| A Clinical Trial to Assess Subjects With Dry Eye Disease.NCT04971031results2023-03-01Conjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye ChamberRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution | Dry Eye | 158 | 2021-09-08actual | — | 2025-02-24 |
| The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.NCT04207736results2024-11-20Subject-Reported Ocular Itching Score Assessed Over 110 to 210 Minutes in the Allergy ChamberRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution | Allergic Conjunctivitis | 95 | 2021-02-16actual | — | 2024-11-20 |
| RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)NCT03445650results2023-02-09Visual Index Ichthyosis Severity (VIIS) Scaling Score as Assessed by the Investigator in ADX-102 Treated PatientsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical Dermal Cream | Sjogren-Larsson Syndrome | 11 | 2020-01-18actual | — | 2023-02-09 |
| A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye DiseaseNCT03916042results2025-03-03Change From Baseline in Subject-reported Ocular Dryness Score (0 - 100 Visual Analogue Scale (VAS))Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID | Dry Eye | 206 | 2019-11-22actual | — | 2025-03-03 |
| A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic ConjunctivitisNCT03660878results2025-04-08Change From Baseline Ocular Itching Score on High Pollen DaysRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution | Allergic Conjunctivitis | 52 | 2019-11-19actual | — | 2025-04-08 |
| The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseNCT03879863results2025-01-23Subject-reported Ocular Dryness Score (0 - 100 Visual Analogue Scale (VAS))Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Reproxalap Ophthalmic Solution (0.25%) QID, Vehicle Ophthalmic Solution QID, Reproxalap Ophthalmic Solution (0.25%) QID to BID, Vehicle Ophthalmic Solution QID to BID | Dry Eye | 422 | 2019-10-04actual | — | 2025-01-23 |
| SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.NCT03131154results2025-02-10Number of Subjects Who Meet Time to Clearance of Anterior Chamber CellsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: ADX-102 Ophthalmic Solution (0.5%), Vehicle of ADX-102 Ophthalmic Solution | Non-infectious Anterior Uveitis | 123 | 2019-04-19actual | — | 2025-02-10 |
| A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure ChamberNCT03709121results2025-02-24Subject-Reported Ocular Itching ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution | Conjunctivitis, Allergic | 70 | 2019-03-20actual | — | 2025-02-24 |
| ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic ConjunctivitisNCT03494504results2025-02-11Subject-reported Ocular Itching ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution | Allergic Conjunctivitis | 318 | 2018-11-05actual | — | 2025-02-11 |
| A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye DiseaseNCT03404115results2025-02-06Efficacy of ADX-102 on the Ora Calibra® Discomfort & 4-Symptom Questionnaire for Dryness.Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.1%), Vehicle Ophthalmic Solution | Dry Eye Syndrome | 300 | 2018-07-11actual | — | 2025-02-06 |
| A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye SyndromeNCT03162783results2025-01-16Efficacy of ADX-102 on Ocular Discomfort Using the Ora Calibra® Ocular Discomfort Scale.Randomized · Quadruple-masked · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ADX-102 Ophthalmic Solution (0.5%), ADX-102 Ophthalmic Solution (0.1%), ADX-102 Ophthalmic Lipid Solution (0.5%) | Dry Eye Syndromes | 51 | 2017-07-06actual | — | 2025-01-16 |
| A Study of ADX-102 in Subjects With Allergic ConjunctivitisNCT03012165results2023-01-09Ocular Itching Evaluated by the Subject at 10(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15.Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ADX-102 Ophthalmic Drops (0.5%), ADX-102 Ophthalmic Drops (0.1%), Vehicle of ADX-102 Ophthalmic Drops | Conjunctivitis, Allergic | 154 | May 2017actual | — | 2023-01-09 |
| A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)NCT02402309results2022-12-13Number of Participants Experiencing a Serious Adverse Event (SAE).Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Active topical NS2 1% dermatologic cream, Vehicle placebo 0.0% NS2 dermatologic cream | Sjögren-Larsson Syndrome | 12 | May 2016actual | — | 2022-12-13 |
| A Safety and Efficacy Study of NS2 in Patients With Anterior UveitisNCT02406209results2023-03-27Anterior Chamber Cell Grade at Week 8Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: NS2, Prednisolone acetate ophthalmic suspension (1%) | Non-infectious Anterior Uveitis | 45 | Apr 2016actual | — | 2023-03-27 |
| A Safety and Activity Study of NS2 in Subjects With Allergic ConjunctivitisNCT02578914results2023-12-05Ocular Itching Score at Day 14, 60 Minutes Into the Allergen ChallengeRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: NS2 Ophthalmic Drops (0.5%), NS2 Ophthalmic Drops Vehicle (0.0%) | Allergic Conjunctivitis, Seasonal Allergies | 100 | Dec 2015actual | — | 2023-12-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19